Thank you, operator, and thank you to all of you for joining us today.
I'll start with a business update before I hand the call over to Bob to review our Q1 financial performance.
Our Commercial Leader, Michael Newton; and Executive Chairwoman, Valerie Palmieri, are also here with us and will be available for questions later in the call.
During my first 2 months as CEO of Aspira, I have focused on validating our strategic priorities and aligning resources to the areas of the business that we believe are most likely to contribute to short and long-term growth.
That effort has included focusing our attention on volume growth in our core business, allocating R&D resources to the products that we believe are most likely to drive commercial success and rationalizing our cash usage across the business.
diseases last achieve were the most our of with the the I health successful said ability excellence. women to our dimensions: ability mission gynecological and year I across time XXXX growth, together, we believe outcomes to X As make on innovation our operational relies to improve
initial around and I'm drivers, worked to progress. I've value hard align these our with leadership our team pleased
over the can to acceleration I with see we confidence of poised are rest say that year. the significant
speak going a leadership I'm development share value moment, but to our to each an driver first, team. about to in I'd like exciting
Today, we are that announcing Dr.
Aspira Officer. Phan be joining Scientific Chief as Ryan Operating and will our
Dr.
and us where Phan from Medical Senior he CareDx, Vice is Lab joins currently Director. Services President of
world-class experience, institutions, strategic the from and combined and systems is extensive our aligned biotech with care His commercial and health industry, priorities. rare academic ranging
We believe pipeline strengthen targeted will operations our accelerate our and this appointment development.
Dr.
key of chain, team, was regulatory Phan supply and executive compliance service led affairs manufacturing, clinical engineering leadership he and where and member clinical pipeline, testing automation a operations, development divisions. the CareDx
In testing and programs Permanente was testing. strategic Dr. to clinical Kaiser where and Northern in accredited expansion Genetic expansion to and addition, series Director related at Head laboratory a licensed the Managing growth Cytogenic played California, the role joining revenues company's of CAP and Director led Pathology Phan key in portfolio. of of Regional laboratories CareDx, company's clinical the the and he and as of served Molecular CLIA and Medical Prior he development, a
where Medical University School, Harvard Dr. of Ryan the in our California at of Cancer portfolio the Institute his Hematopathology. and member is California faculty Los Phan a product He we is Berkeley, Atlas of received diagnostic our He Bachelor's he the fellow post-doctoral coauthored Phan the Los Angeles leader as published of Research academic training clinical textbook, was academic Society has to medicine. of his the prolific Phan PhD expansion numerous papers medical operations and believe University Dr. that, Dr. Medical Before his from highly Angeles degree completed and need Center. and at from VA Columbia I University. the American our enhance was accelerate we and grow. at a scholar. scale efforts, innovation Hematology at
with potential Aspira's talent Ryan Fortunately, us be and better to to He joining will be will few with substantial our and just providers earnings his in women next saw call. quarterly providing weeks gynecological develop decided tools on to health diseases. treat a
our Now core growth. let's talk about business, starting with
of with XX.X%, January. promising X.X% quarter volume early increase days day over average May The very however, per are the average for By daily so struggled over of commercial sales OVA of in March. team achieving of to revenues volume many the sales faced recovered throughout the of into The which threatened surprisingly, sales in $X.X achieved million, quarter was quarter, we companies had rapidly. and other XXXX. of compared an quarter. improvements when increase daily the XX.X%, Our first volume surge with Perhaps, started in our though XX.X% volume for January. sector, OVA low March, we plans, topline the increase to diagnostic the month company. the saw in compared sequentially fourth Average whom not in X.X% year XXXX, opportunities volume, an increased both impacted of significantly new our and of the another COVID Even throes the Unlike first growth in April far COVID continued XX.X% XXs. the volume surge, to the record aggressive challenges additional daily a
no wasted Newton, impact. Michael Commercial, of Head new in an Our time making
a of and executed deploy experience we in reorganization our for personnel relevant most commercial portfolio. disclosed, skills to the team with previously March the effectively As
and we at taken paying also efforts look incentive off efficiency. the have of These plans fresh to sales have in in our a terms appear We be territories sales place force. only with We achieved mentioned yet increased from the March in QX sales we XX X ended salespeople, end XXXX, and April. up in record previously of incrementally volume sales volume the for
team indicator and growth by despite and to In the We the of is the in a roles, high fourth first quarter adding the XXXX, new potential sales an approximately An January. professionals ordering XX of compared first X% end process slow plan leading increase for to created are of the XXX field regarding product sales our future compared OVA a in approximately have XXXX. XX% quarter physicians. quarter newly the time, to XXXX, in increase start of ordered of record first to XXXX, physicians an of important the
incremental to rest for We drive volume the expect these physicians of XXXX.
and towards our of price as focus drivers on volume the the topline Looking will of rest growth. both leadership year, team
maximum refresh the commercial of we of alignment have our they for help As of team improved are the reimbursement and impact. sales positioned the part ensure organization, to
of Illinois, secured health This end, their push other systems nationally have you to active for Advantage series retired reach the and of want launched groups, accelerated underserved with clinics to untapped secured continue families, progress we we pools hospital where potential assure large, of in adoption, strategic payer and at Medicare includes I We our have we previously that super to of military rapidly health to where and physician expand we country a our continue that high-volume favorable physician To new hard large Medicare and that market-making states explore sprints, York, organization. and New creating have reimbursement. relatively pricing work the will areas and such aimed like partnerships Medicaid growth. populations Georgia and as populations. especially whether and in in women's areas sales California,
and products a and final the an of distribute we with while in fact, have to disclose additional negotiating co-market too OVA In to in the share stages are agreement it soon our to expect weeks. information partner to is information, coming detailed commercial
our are to products. drive the we key adoption have of in and future these distribution we believe As of existing rapid said the products relationships will past,
now our innovation product to an on pipeline. Let's turn update and
We OVA The achieved milestones This the step ovarian cancer ovarian year been Informatics. for important already deep our OvaWatch a analytical in accepted our of OvaWatch, launch next-generation algorithm, was publication several to cancer products. Clinical detection of critical validation a towards JCO manuscript, the of have respect this with assessment tool. study network Cancer for neural has risk online
that phases. occur expect finalizing depend the later plan single-use completed launch clinical we intend result, fall. results to commercialization for in with and launch the we test We plan in year. to The the the on shifted over X the be timing validation As to a a this OvaWatch have the to summer which OvaWatch, will publish of study will
interim be met. include launch patients, study. successful the and monitoring from validation to clinical real-world believe launch The prerequisites serial for We for We for reimbursement. which expect planned test will had a both the ongoing data driving completion the this of upon instrumental adoption been of commercial study, all other XXXX is
or findings. strong believe have of sensitivity the product solution diagnostic genetically ahead technology LDT, to who with respect for diagnostic to that line, our Dana-Farber strategic an protein-based initial a personalized previously the high endometriosis this as a commercially We Test, than Institute, groundbreaking Harvard our breakthrough patients a deliver microRNA were have designation. our the demonstrated decision ovarian risk we upon have predisposed Looking development rather strong to develop agreement specificity Laboratory OVA potential pursuing made on disclosed, With device of cancer. research viable we coupled collaboration product, strategic with to by build will the Cancer technology Developed
path, was FDA reasons the program, year. achieving streamlined breakthrough attractive to eliminated device most the was which the reimbursement companies of One last pursue for through
an out breakthrough our product LDT, the path we While are ruling market the diagnostic in for medical to future. now believe appropriate endometriosis we designation FDA device not most is
volume, the to on of priority activities, final people spending the our of seem Our that excellence. of ROI discretionary and strategic driving continue speaks resources, In where OVA those have to leaders with controls appropriately implemented we at Outside especially we to to growth. focus to diagnostic and allocate a we the business the asked and our time, and pace higher our This respect operational cash talent will sales our I've with continue Bob we focus so on especially our with how process to spend. a also to our people, adoption, prudent and the taken endometriosis our priorities, hard is products. first-generation To I clear, drive cost scaling adoption year. those be significantly, in need, at business have endometriosis our broad and operate reserves. the over we of areas be line that products is back in improvement look have and at and infrastructure accelerated price remainder aimed to technology OVA ourselves additional development and funds discretionary do advance be product. challenged development spending have we'll pulled of
term. to However, priorities ROI the spending across to expanding challenge organization, plan we we other and focus near to from the will continue in strategic our the refrain
Over an our hand talk financial team, Bob of very Bob. rest flow firmly it cash I'll year. to executive for managing With you, over about to our quarter As closely are that, we the performance. to the committed to first
